Akero Therapeutics, Inc. (AKRO)
Company Description
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies.
Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Dr. Andrew Cheng M.D., Ph.D. |
Contact Details
Address: 601 Gateway Boulevard, Suite 350 South San Francisco, California 94080 United States | |
| Phone | 650-487-6488 |
| Website | akerotx.com |
Stock Details
| Ticker Symbol | AKRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001744659 |
| CUSIP Number | 00973Y108 |
| ISIN Number | US00973Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive Vice President, Chief Operating Officer and Secretary |
| Dr. Timothy Rolph | Co-Founder and Chief Scientific Officer |
| William R. White J.D. | Executive Vice President, Chief Financial Officer, Treasurer and Head of Corporate Development |
| Catriona Yale | Executive Vice President and Chief Development Officer |
| John J. Schembri | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 29, 2023 | 144 | Filing |
| Dec 18, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 10, 2023 | 8-K | Current Report |
| Oct 2, 2023 | 144 | Filing |
| Oct 2, 2023 | 144 | Filing |
| Sep 12, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 28, 2023 | 144 | Filing |
| Aug 11, 2023 | 8-K | Current Report |